Abstract
There is still a significant portion of gynaecological cancer patients that do not respond well to immune-based cancer therapies. Results of a phase II clinical trial demonstrated the efficacy of the PD-1 inhibitor in advanced cervical cancer which led to Food and Drug Administration (FDA) approval. However, 5-year relative survival for these patients is still less than 20%. In ovarian ca…